Catalent (CTLT) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- BofA lists top 5 themes driving next $1tn in incremental semi sales
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Catalent, Inc. Reports Second Quarter 2016 Results
February 9, 2016 4:16 PM ESTRevenue in line with prior year as reported and increased 6% in constant currency to $454.9 million from second quarter 2015 Adjusted Net Income totaled $44.9 million, or $0.36 per diluted share Entered into a research collaboration with Roche to develop next generation molecules using Catalents proprietary SMARTag technology Announced a long-term exclusive agreement with Pfizer to produce Nexium® 24HR, its leading OTC heartburn medication
SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc. (NYSE:... More
